Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by G. Salles
Refinement of Mum1 Expression Threshold for Double Positive Cd10+ Mum1+ Diffuse Large B Cell Lymphoma Allows a Better Cell of Origin Classification for GCB Subtype
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Polarix: A Phase 3 Study of Polatuzumab Vedotin (Pola) Plus R-CHP Versus R-Chop in Patients (Pts) With Untreated DLBCL
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Tumor Genomic Copy Number Abnormalities Analyzed by High Resolution SNP Array Impact Outcome of Primary CNS Lymphoma: A Retrospective Analysis on 68 Patients
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Cause of Death in Follicular Lymphoma in the Rituximab Era: A Pooled Analysis of French and Us Cohorts
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Cd20-TCB (Rg6026), a Novel “2:1” Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Interim Report From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Efficacy and Safety of Obinutuzumab + Lenalidomide + Atezolizumab in Patients With Relapsed or Refractory Follicular Lymphoma: Primary Analysis of a Phase 1b/2 Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Obinutuzumab Plus Dhap Followed by Autologous Stem Cell Transplantation (Asct) Plus Obinutuzumab Maintenance Provides a High MRD Response Rate in Untreated MCL Patients. Results of Lyma-101 Trial, a Lysa Group Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Rituximab Plus Lenalidomide Is as Effective as Immunochemotherapy in the Eradication of Molecular Disease in Untreated Follicular Lymphoma: Relevance Lysa Ancillary Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
‹
1
2
3
›
